(UTHR) United Therapeutics - Overview
Stock: Treating Pulmonary Arterial Hypertension
| Risk 5d forecast | |
|---|---|
| Volatility | 42.6% |
| Relative Tail Risk | -21.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.21 |
| Alpha | 56.34 |
| Character TTM | |
|---|---|
| Beta | 0.617 |
| Beta Downside | 1.052 |
| Drawdowns 3y | |
|---|---|
| Max DD | 33.00% |
| CAGR/Max DD | 1.05 |
EPS (Earnings per Share)
Revenue
Description: UTHR United Therapeutics March 01, 2026
United Therapeutics (NASDAQ: UTHR) is a biotechnology firm focused on developing and commercializing therapies for chronic, life-threatening conditions, primarily pulmonary arterial hypertension (PAH) and high-risk neuroblastoma. Its product portfolio includes inhaled and oral PAH treatments (Tyvaso DPI, Tyvaso solution, Remodulin, Orenitram, Adcirca), the monoclonal antibody Unituxin for neuroblastoma, and delivery systems such as the Remunity Pump. The company is also advancing pipeline candidates-including RemoPro, Ralinepag, the gene-therapy Aurora-GT, and nebulized Tyvaso for idiopathic pulmonary fibrosis-as well as xenograft organ-product platforms.
In its most recent fiscal year (FY 2025), United Therapeutics reported revenue of **$1.62 billion**, a **12% year-over-year increase**, driven by strong sales of Orenitram and the expanding Tyvaso line. The balance sheet remains robust with **$2.24 billion** in cash and short-term investments, supporting continued R&D spend of **$420 million**, which represents roughly **26%** of total revenue.
The PAH market is projected to grow at a **CAGR of 6.3%** through 2030, propelled by rising diagnosis rates and an aging population, while the broader biotech sector benefits from heightened investor appetite for specialty therapeutics and gene-therapy platforms-trends that align with United Therapeutics’ pipeline focus.
For deeper quantitative analysis, you might explore ValueRay’s data on UTHR.
Headlines to watch out for
- Tyvaso sales growth drives pulmonary hypertension revenue
- Remodulin and Orenitram sales contribute to PAH treatment
- Pipeline advancements in xenotransplantation offer future growth
- Regulatory approvals for new indications expand market reach
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 1.33b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA -1.47 > 1.0 |
| NWC/Revenue: 98.72% < 20% (prev 109.0%; Δ -10.26% < -1%) |
| CFO/TA 0.20 > 3% & CFO 1.56b > Net Income 1.33b |
| Net Debt (-1.56b) to EBITDA (1.81b): -0.86 < 3 |
| Current Ratio: 6.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.9m) vs 12m ago -1.64% < -2% |
| Gross Margin: 87.92% > 18% (prev 0.89%; Δ 8703 % > 0.5%) |
| Asset Turnover: 41.76% > 50% (prev 39.07%; Δ 2.68% > 0%) |
| Interest Coverage Ratio: 88.27 > 6 (EBITDA TTM 1.81b / Interest Expense TTM 19.5m) |
Altman Z'' 10.00
| A: 0.40 (Total Current Assets 3.70b - Total Current Liabilities 560.6m) / Total Assets 7.88b |
| B: 1.09 (Retained Earnings 8.56b / Total Assets 7.88b) |
| C: 0.23 (EBIT TTM 1.72b / Avg Total Assets 7.62b) |
| D: 10.92 (Book Value of Equity 8.56b / Total Liabilities 783.8m) |
| Altman-Z'' Score: 19.14 = AAA |
Beneish M -2.85
| DSRI: 1.13 (Receivables 350.2m/279.3m, Revenue 3.18b/2.88b) |
| GMI: 1.01 (GM 87.92% / 89.24%) |
| AQI: 1.01 (AQ_t 0.31 / AQ_t-1 0.31) |
| SGI: 1.11 (Revenue 3.18b / 2.88b) |
| TATA: -0.03 (NI 1.33b - CFO 1.56b) / TA 7.88b) |
| Beneish M-Score: -2.85 (Cap -4..+1) = A |
What is the price of UTHR shares?
Over the past week, the price has changed by +7.45%, over one month by +13.23%, over three months by +10.51% and over the past year by +68.56%.
Is UTHR a buy, sell or hold?
- StrongBuy: 6
- Buy: 2
- Hold: 6
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the UTHR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 583.9 | 9% |
| Analysts Target Price | 583.9 | 9% |
UTHR Fundamental Data Overview March 11, 2026
P/E Forward = 18.2482
P/S = 7.3784
P/B = 3.2706
P/EG = 2.0517
Revenue TTM = 3.18b USD
EBIT TTM = 1.72b USD
EBITDA TTM = 1.81b USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = -1.56b USD (from netDebt column, last quarter)
Enterprise Value = 21.93b USD (23.48b + (null Debt) - CCE 1.56b)
Interest Coverage Ratio = 88.27 (Ebit TTM 1.72b / Interest Expense TTM 19.5m)
EV/FCF = 21.07x (Enterprise Value 21.93b / FCF TTM 1.04b)
FCF Yield = 4.75% (FCF TTM 1.04b / Enterprise Value 21.93b)
FCF Margin = 32.70% (FCF TTM 1.04b / Revenue TTM 3.18b)
Net Margin = 41.94% (Net Income TTM 1.33b / Revenue TTM 3.18b)
Gross Margin = 87.92% ((Revenue TTM 3.18b - Cost of Revenue TTM 384.4m) / Revenue TTM)
Gross Margin QoQ = 86.91% (prev 87.38%)
Tobins Q-Ratio = 2.78 (Enterprise Value 21.93b / Total Assets 7.88b)
Interest Expense / Debt = unknown (Interest Expense 3.10m / Debt none)
Taxrate = 17.95% (79.7m / 444.0m)
NOPAT = 1.41b (EBIT 1.72b * (1 - 17.95%))
Current Ratio = 6.60 (Total Current Assets 3.70b / Total Current Liabilities 560.6m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = -0.86 (Net Debt -1.56b / EBITDA 1.81b)
Debt / FCF = -1.50 (Net Debt -1.56b / FCF TTM 1.04b)
Total Stockholder Equity = 6.92b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.51% (Net Income 1.33b / Total Assets 7.88b)
RoE = 19.30% (Net Income TTM 1.33b / Total Stockholder Equity 6.92b)
RoCE = 23.52% (EBIT 1.72b / Capital Employed (Total Assets 7.88b - Current Liab 560.6m))
RoIC = 20.27% (NOPAT 1.41b / Invested Capital 6.97b)
WACC = 8.19% (E(23.48b)/V(23.48b) * Re(8.19%) + (debt-free company))
Discount Rate = 8.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.93%
[DCF] Terminal Value 79.13% ; FCFF base≈1.06b ; Y1≈1.19b ; Y5≈1.61b
[DCF] Fair Price = 645.6 (EV 26.74b - Net Debt -1.56b = Equity 28.29b / Shares 43.8m; r=8.19% [WACC]; 5y FCF grow 15.07% → 2.90% )
EPS Correlation: 70.26 | EPS CAGR: 12.02% | SUE: 1.36 | # QB: 1
Revenue Correlation: 97.03 | Revenue CAGR: 15.39% | SUE: -0.62 | # QB: 0
EPS next Quarter (2026-06-30): EPS=6.98 | Chg7d=+0.036 | Chg30d=-0.190 | Revisions Net=-3 | Analysts=11
EPS current Year (2026-12-31): EPS=28.19 | Chg7d=-0.169 | Chg30d=-0.400 | Revisions Net=-1 | Growth EPS=+1.2% | Growth Revenue=+5.1%
EPS next Year (2027-12-31): EPS=32.10 | Chg7d=+0.376 | Chg30d=+1.327 | Revisions Net=+5 | Growth EPS=+13.9% | Growth Revenue=+12.7%
[Analyst] Revisions Ratio: -0.60 (1 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.0% (Discount Rate 8.2% - Earnings Yield 5.2%)
[Growth] Growth Spread = +1.3% (Analyst 4.3% - Implied 3.0%)